biomedicina slovenica


pr=Čufer : 581

  1. Bitenc Marko; Čufer Tanja; Kern Izidor; Miklavčič Martina; Petrovic Sabrina; Groznik Vida; Sadikov Aleksander
    Real-life long-term outcomes of upfront surgery in patients with resectable stage I-IIIA non-small cell lung cancer
    2022
  2. Illini Oliver; Fabikan Hannah; Swalduz Aurélie; Vikström Anders; Krenbek Dagmar; Schumacher Michael; Dudnik Elizabeth; Studnicka Michael; Öhman Ronny; Wurm Robert; Čufer Tanja; Mohorčič Katja; Hochmair Maximilian J
    Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP)
    2022
  3. Ivanović Marija; Knez Lea; Herzog Ana; Kovačević Mile; Čufer Tanja
    Immunotherapy for metastatic non-small cell lung cancer
    2021
  4. Zadnik Vesna; Žagar Tina; Tomšič Sonja; Lokar Katarina; Duratović Konjević Amela; Zakotnik Branko; Aničin Aleksandar; Bešić Nikola; Borštnar Simona; Čarman Janka; Čufer Tanja; Dremelj Marta; Grašič-Kuhar Cvetka; Hočevar Marko; Jazbec Janez; Jezeršek Novaković Barbara; Kobal Borut; Marinko Tanja; Mavčič Blaž; Mesti Tanja; Novak Marko; Ocvirk Janja; Omejc Mirko; Smrdel Uroš; Smrkolj Tomaž; Strojan Primož; Šeruga Boštjan; Škof Erik; Škrbinc Breda; Štupnik Tomaž; Unk Mojca; Velenik Vaneja; Vidergar-Kralj Barbara; Vrankar Martina; Zadravec-Zaletel Lorna; Zobec Logar Helena Barbara; Zver Samo; Žgajnar Janez; Kovač Viljem; Primic-Žakelj Maja; Strojan Primož
    Survival of cancer patients, diagnosed in 1997-2016 in Slovenia
    2021
  5. Zadnik Vesna; Žagar Tina; Tomšič Sonja; Lokar Katarina; Duratović Konjević Amela; Zakotnik Branko; Aničin Aleksandar; Bešić Nikola; Borštnar Simona; Čarman Janka; Čufer Tanja; Dremelj Marta; Grašič-Kuhar Cvetka; Hočevar Marko; Jazbec Janez; Jezeršek Novaković Barbara; Kobal Borut; Marinko Tanja; Mavčič Blaž; Mesti Tanja; Novak Marko; Ocvirk Janja; Omejc Mirko; Smrdel Uroš; Smrkolj Tomaž; Strojan Primož; Šeruga Boštjan; Škof Erik; Škrbinc Breda; Štupnik Tomaž; Unk Mojca; Velenik Vaneja; Vidergar-Kralj Barbara; Vrankar Martina; Zadravec-Zaletel Lorna; Zobec Logar Helena Barbara; Zver Samo; Žgajnar Janez; Kovač Viljem; Primic-Žakelj Maja; Strojan Primož
    Preživetje bolnikov z rakom, zbolelih v letih 1997-2016 v Sloveniji
    2020
  6. Koren Ana; Rijavec Matija; Krumpestar Tomaž; Kern Izidor; Sadikov Aleksander; Čufer Tanja; Korošec Peter
    Gene expression levels of the prolyl hydroxylase domain proteins PHD1 and PHD2 but not PHD3 are decreased in primary tumours and correlate with poor prognosis of patients with surgically resected non-small-cell lung cancer
    2021
  7. Brčić Luka; Klikovits Thomas; Megyesfalvi Zsolt; Mosleh Berta; Sinn Katharina; Hritcu Richard; Laszlo Viktoria; Čufer Tanja; Rozman Aleš; Kern Izidor; Mohorčič Katja
    Prognostic impact of PD-1 and PD-L1 expression in malignant pleural mesothelioma
    2021
  8. Hochmair Maximilian J; Morabito Alessandro; Hao Desiree; Yang Cheng-Ta; Soo Ross A; Yang James C-H; Gucalp Rasim; Halmos Balazs; Märten Angela; Čufer Tanja
    Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
    2020
  9. Čufer Tanja
    Novosti v sistemskem zdravljenju raka pljuč s poudarkom na imunoterapiji
    [Advancements in systemic treatment of lung cancer with a focus on immunotherapy]
    2020
  10. Čufer Tanja; Ciuleanu Tudor; Berzinec Peter; Galffy Gabriela; Jakopović Marko; Jassem Jacek; Jovanovic Dragana; MIhaylova Zhasmina; Ostoros Gyula; Thallinger Christiane; Zemanova Milada; Zielinski Christoph
    Access to novel drugs for non-small cell lung cancer in Central and Southeastern Europe
    2020
  11. Čufer N.; Fakin Ana; Hawlina Marko
    Progressive constriction of the visual field in a patient with extensive "dark without pressure" lesions
    2019
  12. Mountzios Giannis; Remon J.; Novello Silvia; Blais N.; Califano R.; Čufer Tanja; Dingemans Anne-Marie C.; Liu S. V.; Peled N.; Pennell N. A.
    Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of >= 1 by the USA Food and Drug Administration
    2019
  13. Hochmair Maximilian J; Morabito Alessandro; Hao Desiree; Yang Cheng-Ta; Soo Ross A; Yang James C-H; Gucalp Rasim; Halmos Balazs; Wang Lara; Märten Angela; Čufer Tanja
    Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
    2019
  14. Janžič Urška; Knez Lea; Janžič Andrej; Čufer Tanja
    Time to access to novel anticancer drugs and the correlation with ESMO-Magnitude of Clinical Benefit Scale in Slovenia
    2019
  15. Lawler Mark; Naredi Peter; Čufer Tanja; Banks Ian; Lievens Yolande; Vassal Giles; Aapro Matti S.; Južnič Sotlar Maja; Philip Thierry; Jassem Jacek
    Moonshot or groundshot
    2017
  16. Dingemans Anne-Marie C.; Hendriks Lizza E. L.; Berghmans Thierry; Levy Antonin; Hasan Baktiar; Faivre-Finn Corinne; Giaj-Levra Matteo; Giaj-Levra Niccolò; Girard Nicolas; Greillier Laurent; Čufer Tanja
    Definition of synchronous oligometastatic non-small cell lung cancer
    2019
  17. Vlačić Gregor; Hoda Mir Alireza; Klikovits Thomas; Sinn Katharina; Gschwandtner Elisabeth; Mohorčič Katja; Schelch Karin; Pirker Christine; Peter-Vörösmarty Barbara; Brankovic Jelena; Čufer Tanja; Rozman Aleš; Kern Izidor
    Expression of FGFR1-4 in malignant pleural mesothelioma tissue and corresponding cell lines and its relationship to patient survival and FGFR inhibitor sensitivity
    2019
  18. Zwitter Matjaž; Čufer Tanja; Vrankar Martina; Kern Izidor; Štupnik Tomaž; Rozman Aleš; Koprivnikar Helena; Zadnik Vesna
    Lung cancer in Slovenia
    2019
  19. Humar Mojca; Kern Izidor; Vlačić Gregor; Hadžić Vedran; Čufer Tanja
    Insulin-like growth factor 1 receptor expression in advanced non-small-cell lung cancer and its impact on overall survival
    2017
  20. Vrdoljak Eduard; Bodoky Gyorgy; Jassem Jacek; Popescu Razvan A.; Pirker Robert; Čufer Tanja; Beslija Semir; Eniu Alexsandru; Todorović Vladimir; Kopečková Katerina
    Expenditures on oncology drugs and cancer mortality-to-incidence ratio in Central and Eastern Europe
    2019
  21. Hochmair Maximilian J; Morabito Alessandro; Hao Desiree; Yang Cheng-Ta; Soo Ross A; Yang James C-H; Gucalp Rasim; Halmos Balazs; Wang Lara; Golembesky Amanda; Märten Angela; Čufer Tanja
    Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
    2018
  22. Begum Mursheda; Lewison Grant; Jassem Jacek; Mixich Vlad; Čufer Tanja; Nurgozhin Talgat; Shabalkin Pavel; Kutluk Tezer; Vokó Zoltán; Radosavljevic Davorin
    Mapping cancer research across Central and Eastern Europe, the Russian Federation and Central Asia
    2018
  23. Rich Anna; Baldwin David R.; Alfageme Inmaculada; Beckett Paul; Berghmans Thierry; Brincat Stephen; Burghuber Otto; Corlateanu Alexandru; Čufer Tanja; Damhuis Ronald
    Achieving thoracic oncology data collection in Europe
    2018
  24. Globočnik Kukovica Marta; Hribernik Nežka; Herzog Ana; Čufer Tanja
    Febrilna nevtropenija in nevtropenija višje stopnje ob adjuvantnem zdravljenju nedrobnoceličnega raka pljuč v vsakodnevni praksi
    [Febrile neutropenia and grade 3/4 neutropenia in daily practice of adjuvant chemotherapy for non-small-cell lung cancer]
    2018
  25. Čufer Tanja; Knez Lea; Mrhar Aleš
    Sistemsko zdravljenje
    2018
  26. Crnjac Anton; Čufer Tanja; Stanič Karmen
    Raki torakalnih organov
    2018
  27. Ryška Ales; Berzinec Peter; Brcic Luka; Čufer Tanja; Dziadziuszko Rafal; Gottfried Maya; Kovalszky Ilona; Olszewski Włodzimierz; Oz Buge; Plank Lukas; Tímár József
    NSCLC molecular testing in Central and Eastern European countries
    2018
  28. Pan Hongchao; Gray Richard James; Braybrooke Jeremy; Davies Christina; Taylor Carolyn; McGale Paul; Peto Richard; Pritchard Kathleen I.; Bergh Jonas; Dowsett Mitch; Čufer Tanja
    20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years
    2017
  29. Sonnenblick Amir; Agbor-Tarh Dominique; Bradbury Ian; Cosimo Serena Di; Azim Hatem A.; Fumagalli Debora; Sarp Severine; Andersson Michael; Kroep Judith; Čufer Tanja
    Impact of diabetes, insulin, and metformin use on the outcome of patients with human epidermal growth factor receptor 2-positive primary breast cancer
    2017
  30. Čufer Tanja; Vončina Marjana
    Konoplja ne pozdravi raka
    2017
  31. Vončina Marjana; Rajer Mirjana; Čufer Tanja
    Rakavi bolniki v kleščah zaslužkarjev
    2017
  32. Rajer Mirjana; Muhič Neža; Čufer Tanja
    Rak in komplementarne oz. alternativne metode zdravljenja
    2017
  33. Rot Mitja; Kern Izidor; Čufer Tanja; Mohorčič Katja
    Detectability of activating and resistance EGFR mutations in plasma
    2017
  34. Janžič Urška; Kern Izidor; Janžič Andrej; Čavka Luka; Čufer Tanja
    PD-L1 expression in squamous-cell carcinoma and adenocarcinoma of the lung
    2017
  35. Čufer Tanja; Lesnik Blaž
    Če kdo trdi, da ima zdravilo za raka, ga mora takoj registrirati
    2017
  36. Hribernik Nežka; Globočnik Kukovica Marta; Herzog Ana; Čufer Tanja
    Febrile neutropenia and neutropenia grade 3/4 in daily practice adjuvant chemotherapy for non-small-cell lung cancer
    2017
  37. Rajer Mirjana; Herzog Ana; Čufer Tanja
    Survival of elderly advanced NSCLC patients treated with TKIS
    2017
  38. Unk Mojca; Mohorčič Katja; Osrajnik Ilonka; Čufer Tanja
    Slovenske smernice sistemskega zdravljenja pljučnega raka 2017
    [Lung cancer - Slovenian clinical practice guidelines in systemic treatment 2017]
    2017
  39. Turnšek Hitij Nina; Kern Izidor; Sadikov Aleksander; Knez Lea; Stanič Karmen; Zwitter Matjaž; Čufer Tanja
    Immunohistochemistry for EGFR mutation detection in non-small-cell lung cancer
    2017
  40. Koren Ana; Rijavec Matija; Sodja Eva; Kern Izidor; Sadikov Aleksander; Kovač Viljem; Korošec Peter; Čufer Tanja
    High BMI1 mRNA expression in peripheral whole blood is associated with favorable prognosis in advanced non-small cell lung cancer patients
    2017
  41. Omersa Daniel; Čufer Tanja; Marčun Robert; Lainščak Mitja
    Echocardiography and cardiac biomarkers in patients with non-small cell lung cancer treated with platinum-based chemotherapy
    2017
  42. Čufer Tanja
    Systemic treatment of lung cancer
    2016
  43. Janžič Urška; Kern Izidor; Janžič Andrej; Čavka Luka; Čufer Tanja
    PD-L1 expression in NSCLC
    2016
  44. Ribnikar Domen; Sousa Berta; Čufer Tanja; Cardoso Fatima
    Extended adjuvant endocrine therapy
    2017
  45. Kern Izidor; Kovačević Mile; Janžič Urška; Čufer Tanja
    PD-L1 expression in NSCLC and biopsy size
    2016
  46. Čufer Tanja
    Imunoterapija
    2016
  47. Čufer Tanja
    Katerih novosti v svoji klinični praksi se veselim
    2016
  48. Buturović-Ponikvar Jadranka; Gubenšek Jakob; Arnol Miha; Adamlje Tone; Ceglar Zlata; Damevska Gabriela; Globokar Mateja; Černe Senka; Čufer Andrej; Drozg Andrej; Ekart Robert; Knap Bojan; Kapun Sonja; Kralj Lopert Simona; Klančič Dimitrij; Kunc-Rešek Natalija; Kralj Stojan; Malovrh Marko; Močivnik Marjan; Novljan Gregor; Romozi Karmen; Rus Igor; Saksida Silvana; Vujkovac Bojan; Ponikvar Rafael
    Renal replacement therapy in Slovenia
    2016
  49. Vrdoljak Eduard; Bodoky Gyorgy; Jassem Jacek; Popescu Razvan A.; Mardiak Jozef; Pirker Robert; Čufer Tanja; Beslija Semir; Eniu Alexsandru; Todorović Vladimir
    Cancer Control in Central and Eastern Europe
    2016
  50. Novello S.; Barlesi F.; Califano R.; Čufer Tanja; Ekman S.; Giaj-Levra Piero; Kerr K.; Popat Sanjay; Reck M.; Senan S.
    Metastatic non-small-cell lung cancer
    2016
  51. Koren Ana; Čufer Tanja; Korošec Peter
    Pomen tumorskih matičnih celic in epitelno-mezenhimskega prehoda pri napredovanju nedrobnoceličnega raka pljuč
    [The importance of cancer stem cells and epithelial-mesenchymal transition in the progression of non-small cell lung cancer]
    2016
  52. Sodja Eva; Čufer Tanja; Korošec Peter
    Vpliv izražanja molekularnih označevalcev rakavih matičnih celic v krvi in tumorskem tkivu na prognozo bolnikov s pljučnim rakom
    [The impact of cancer stem cell molecular markers expression in blood and tumour tissue on prognosis of lung cancer patients]
    2015
  53. Sodja Eva; Rijavec Matija; Koren Ana; Sadikov Aleksander; Korošec Peter; Čufer Tanja
    The prognostic value of whole blood SOX2, NANOG and OCT4 mRNA expression in advanced small-cell lung cancer
    2016
  54. Benedik Jernej; Globokar Tina; Čufer Tanja; Červek Jožica
    Rak sečil
    2005
  55. Čufer Tanja
    Hormonsko zdravljenje raka
    2005
  56. Globokar Tina; Benedik Jernej; Červek Jožica; Čufer Tanja
    Rak ledvic
    2005
  57. Čufer Tanja
    Novi pristopi k zdravljenju ter raziskovanju raka in dostop do teh zdravljenj
    [New approaches to cancer treatment and research and access to them]
    2016
  58. von Minckwitz Gunter; Čufer Tanja
    Trastuzumab treatment beyond progression in patients with HER-2 positive metastatic breast cancer
    2007
  59. Čufer Tanja
    Zgovorna biologija
    2006
  60. Čufer Tanja
    Onkogen usmerena terapija kod nemikrocelularnog karcinoma pluća
    [Oncogene-directed therapies in non-small-cell lung cancer]
    2015
  61. Ryska A.; Dziadziuszko R.; Olszewski W.; Berzinec P.; Öz B.; Gottfried M.; Čufer Tanja; Samaržija Miroslav; Plank L.; Ostoros Gy; Tímár József
    A tüdőrák molekuláris diagnosztikája
    2015
  62. Tryfonidis Konstantinos; Čufer Tanja
    A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378).
    2016
  63. Čufer Tanja
    Aromatase inhibitors versus tamoxifen in early breast cancer
    2015
  64. Čufer Tanja
    Adjuvant bisphosphonate treatment in early breast cancer
    2015
  65. Hortobagyi Gabriel N.; El-Saghir Nagi S.; Čufer Tanja; Cazap Eduardo L.; Guzman Roselle de; Othieno-Abinya Nicholas Anthony; Sanchez Jose Angel; Pyle Doug
    The American Society of Clinical Oncology's efforts to support global cancer medicine
    2016
  66. Šamija Mirko; Čufer Tanja; Pechersdorfer Martin; Vrbanec Damir; Beketić-Orešković Lidija; Jassen Jacek; Vrdoljak Eduard; Snoj Marko
    Breast cancer tumor board
    2009
  67. Šamija Mirko; Čufer Tanja; Pechersdorfer Martin; Vrbanec Damir; Beketić-Orešković Lidija; Jassen Jacek; Vrdoljak Eduard; Snoj Marko
    Breast cancer tumor board
    2009
  68. Šamija Mirko; Čufer Tanja; Pechersdorfer Martin; Vrbanec Damir; Beketić-Orešković Lidija; Jassen Jacek; Vrdoljak Eduard; Snoj Marko
    Breast cancer tumor board
    2009
  69. Šamija Mirko; Čufer Tanja; Pechersdorfer Martin; Vrbanec Damir; Beketić-Orešković Lidija; Jassen Jacek; Vrdoljak Eduard; Snoj Marko
    Breast cancer tumor board
    2009
  70. Šamija Mirko; Čufer Tanja; Pechersdorfer Martin; Vrbanec Damir; Beketić-Orešković Lidija; Jassen Jacek; Vrdoljak Eduard; Snoj Marko
    Breast cancer tumor board
    2009
  71. Červek Jožica; Matos Erika; Čufer Tanja
    Gemcitabine in combination with cisplatin in bladder sparing treatment
    2002
  72. Grašič-Kuhar Cvetka; Čufer Tanja; Golouh Rastko
    Highly effective treatment with trastuzumab in a chemotherapy-resistant metastatic breast carcinoma
    2002
  73. Čufer Tanja
    Systemic therapy of breast cancer
    2002
  74. Strojnik Ksenija; Pajk Bojana; Čufer Tanja
    Neutropenia in breast cancer patients treated with neo/adjuvant chemotherapy containing docetaxel and/or epidoxorubicin
    2007
  75. Ravnik Maja; Takač Iztok; Arko Darja; Gorišek Borut; Čas-Sikošek Nina; Lampelj Maja; Ravnik Janez; Čufer Tanja
    Correlation between invasive markers (uPA/PAL-1) and HER 2 status in early breast cancer
    2007
  76. Čufer Tanja
    Tarčno zdravljenje raka
    2007
  77. Čufer Tanja
    Update on therapy of breast cancers
    2007
  78. Ravnik Maja; Takač Iztok; Arko Darja; Gorišek Borut; Čas-Sikošek Nina; Lampelj Maja; Ravnik Janez; Čufer Tanja
    Correlation between invasive markers (uPA/PAI-1) and HER-2 status in early breast cancer
    2007
  79. Čufer Tanja
    Imunoterapija
    2015
  80. Slanc Janika; Čufer Tanja; Kozjek Franc; Sonc Monika
    Preliminary study investigating short-term treatment related quality of life in cisplatin and 5-fluorouracil versus etoposide as salvage therapy in metastatic breast cancer patients
    2003
  81. Lesnik Tina; Pfeifer Marija; Matos Erika; Pajk Bojana; Snoj Nataša; Sadikov Aleksander; Čufer Tanja
    The evaluation of the pituitary-ovarian axis in early breast cancer (EBC) patients (pts) receiving adjuvant hormonal therapy with LHRH agonists with tamoxifen or aromatase inhibitors (AI)
    2007
  82. Strojnik Ksenija; Pajk Bojana; Čufer Tanja
    Neutropenia in breast cancer patients treated with neo/adjuvant chemotherapy containing docetaxel and/or epidoxorubicin
    2007
  83. Knez Lea; Sadikov Aleksander; Jakelj Andraž; Mohorčič Katja; Turnšek Nina; Čufer Tanja
    Overall survival in advanced lung cancer patients proposed initial chemotherapy according to actual chemotherapy delivery
    2015
  84. Globočnik Kukovica Marta; Mohorčič Katja; Sadikov Aleksander; Jakelj Andraž; Čufer Tanja
    Survival of lung cancer patients involved or not into early palliative care setting
    2015
  85. Janžič Urška; Kern Izidor; Čavka Luka; Janžič Andrej; Čufer Tanja
    PD-L1 expression in NSCLC
    2015
  86. Turnšek Nina; Kern Izidor; Sadikov Aleksander; Rot Mitja; Stanič Karmen; Zwitter Matjaž; Čufer Tanja
    Immunohistochemically determined EGFR mutations and selection of patients for EGFR-directed therapy in NSCLC
    2015
  87. Čufer Tanja; Knez Lea
    Pristop k povečanju varnosti sistemskega zdravljenja raka
    2015
  88. Čufer Tanja
    December 2006 San Antonio meeting
    2007
  89. Pajk Bojana; Čufer Tanja
    Current role of ovarien ablation in the treatment of pre-menopausal women with breast cancer
    2006
  90. Režonja Renata; Grabnar Iztok; Mrhar Aleš; Čebron Lipovec Nanča; Čufer Tanja; Vovk Tomaž
    A simple dried blood spot method for clinical pharmacological analyses of etoposide in cancer patients using liquid chromatography and fluorescence detection
    2015
  91. Koren Ana; Rijavec Matija; Kern Izidor; Sodja Eva; Korošec Peter; Čufer Tanja
    BMI1, ALDH1A1, and CD133 transcripts connect epithelial-mesenchymal transition to cancer stem cells in lung carcinoma
    2015
  92. Čufer Tanja
    Letno srečanje ASCO
    2015
  93. Čufer Tanja
    Zagotavljanje varnosti bolnikov pri dolgotrajnem sistemskem zdravljenju raka
    2012
  94. Čufer Tanja; Knez Lea
    Tarčna terapija in imunoterapija pljučnega raka
    2015
  95. Čufer Tanja; Pajk Bojana
    Zagotavljanje varnosti bolnikov na sistemskem zdravljenju raka
    2008
  96. Ramlau Rodryg; Čufer Tanja; Kern Izidor
    Epidermal growth factor receptor mutation-positive non-small-cell lung cancer in the real-world setting in Central Europe
    2015
  97. O'Brien Mary E. R.; Gaafar Rabab; Hasan Baktiar; Menis Jessica; Čufer Tanja; Popat Sanjay; Woll Penella J.; Surmont Veerle; Georgoulias Vassilis; Montes Ana; Blackhall Fiona; Hennig Ivo; Schmid-Bindert Gerald; Baas Paul
    Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy
    2015
  98. Koren Ana; Sodja Eva; Rijavec Matija; Jež Mojca; Kovač Viljem; Korošec Peter; Čufer Tanja
    Prognostic value of cytokeratin-7 mRNA expression in peripheral whole blood of advanced lung adenocarcinoma patients
    2015
  99. Čufer Tanja
    Individualized systemic therapy of non-small cell lung cancer
    2013
  100. Čufer Tanja
    Individualized, biomarker driven systemic therapy of lung cancer
    2013

1 101 201 301 401 501  


New search      Comments      Top of page Institute for Biostatistics and Medical Informatics